This is an open-label, Phase 1 dose escalation and expansion study of NOV140101 (IDX1197HCl) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of IDX1197HCl in patients with advanced solid tumors after failure of standard of care.